AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29907198 — intervention group
Group type: COMPARATOR
Intervention: Daily soap and water bathing
Number of subjects: 325
Study 27750737 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCIS coding strategy
Number of subjects: 22
Study 27750737 — intervention group
Group type: COMPARATOR
Intervention: FSP coding strategy
Number of subjects: 22
Study 24870737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (pemetrexed + bevacizumab)
Number of subjects: 72
Study 24870737 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed group
Number of subjects: 72
Study 24870737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 22401514 — intervention group
Group type: EXPERIMENTAL
Intervention: Gun cabinet installation (early group)
Number of subjects: 0
Study 20116704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound bone surgery tools
Number of subjects: 26
Study 20116704 — intervention group
Group type: COMPARATOR
Intervention: Rotary instruments
Number of subjects: 26
Study 18589123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS) - Group A (n = 21)
Number of subjects: 40
Study 18589123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS) - Group B (n = 19)
Number of subjects: 40
Study 18589123 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS) - Cohorts A plus B (n = 40)
Number of subjects: 40
Study 18589123 — intervention group
Group type: COMPARATOR
Intervention: Continuous mycophenolate mofetil (MMF) - Control group (n = 19)
Number of subjects: 40
Study 16091873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporadic asthma
Number of subjects: 161
Study 16091873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent asthma
Number of subjects: 161
Study 16091873 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent asthma
Number of subjects: 161
Study 16091873 — intervention group
Group type: COMPARATOR
Intervention: No recent asthma
Number of subjects: 161
Study 16091873 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent asthma with low FEV1%
Number of subjects: 161
Study 12432327 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) for uterine distension
Number of subjects: 189
Study 12432327 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution for uterine distension
Number of subjects: 189
Study 10519591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exotropia patients
Number of subjects: 206
Study 10519591 — intervention group
Group type: COMPARATOR
Intervention: Esotropia patients
Number of subjects: 206
Study 10519591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exotropia patients with constant strabismus
Number of subjects: 206
Study 10519591 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller angles of exotropia or esotropia
Number of subjects: 206
Study 10519591 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic disorders
Number of subjects: 206
Study 10519591 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients referred for evaluation of strabismus
Number of subjects: 206
Study 7488474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic extradural analgesia with bupivacaine and sufentanil 20 micrograms kg‐1
Number of subjects: 9
Study 7488474 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 9
Study 2037712 — intervention group
Group type: COMPARATOR
Intervention: CMT 1.5 g orally every 12 hours
Number of subjects: 12
Study 2037712 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT plus sucralfate 1 g orally every 6 hours
Number of subjects: 12
Study 6459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 163
Study 6459363 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 163
Study 6459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (follow-up of 2,298 patients)
Number of subjects: 163
Study 6459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (literature review of 2,306 patients)
Number of subjects: 163
Study 31763984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs) - four escalating doses (37.5-75 million cells)
Number of subjects: 14
Study 31443220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 16
Study 31443220 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg/b.m. (CAF-9)
Number of subjects: 16
Study 31443220 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 11 mg/kg/b.m. (CAF-11)
Number of subjects: 16
Study 27866501 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning to Read in a Healing Classroom (LRHC) program
Number of subjects: 0
Study 27866501 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 0
Study 25889150 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (artemisinin-NQ)
Number of subjects: 176
Study 25889150 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AM-LM)
Number of subjects: 176
Study 25889150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 176
Study 24071915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 55
Study 21229259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-RM squat
Number of subjects: 11
Study 21229259 — intervention group
Group type: COMPARATOR
Intervention: Control (no squat)
Number of subjects: 11
Study 19092106 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (30 mg/day)
Number of subjects: 60
Study 19092106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18042082 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with soluble morning insulin
Number of subjects: 17
Study 18042082 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with soluble + NPH morning insulin
Number of subjects: 17
Study 18042082 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with aspart + NPH morning insulin
Number of subjects: 17
Study 18042082 — intervention group
Group type: COMPARATOR
Intervention: NPH pre-bed during run-in period
Number of subjects: 17
Study 14982565 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg before surgery, followed by 600 mg at 8, 16, and 24 hours postoperatively
Number of subjects: 80
Study 14982565 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin group
Number of subjects: 80
Study 14982565 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 80
Study 11678974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin + glimepiride)
Number of subjects: 372
Study 11678974 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride monotherapy
Number of subjects: 372
Study 11678974 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 372
Study 9879725 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP (0.01‐10 pmol kg(‐1) min(‐1))
Number of subjects: 8
Study 8036292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily in the morning
Number of subjects: 340
Study 8036292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily in the evening
Number of subjects: 340
Study 8036292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms twice daily
Number of subjects: 340
Study 8036292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 3055745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisin ointment
Number of subjects: 41
Study 3055745 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis alone
Number of subjects: 41
Study 3055745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31351869 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, days 1-21) and cetuximab (400 mg/m2 on cycle one, day 1, then 250 mg/m2 once per week) in group 1 (platinum-resistant)
Number of subjects: 62
Study 31351869 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, days 1-21) and cetuximab (400 mg/m2 on cycle one, day 1, then 250 mg/m2 once per week) in group 2 (cetuximab-resistant)
Number of subjects: 62
Study 28952897 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC+VT (standard OTP clinical care plus varenicline)
Number of subjects: 7
Study 28952897 — intervention group
Group type: COMPARATOR
Intervention: SCC (standard OTP clinical care)
Number of subjects: 7
Study 26847368 — intervention group
Group type: EXPERIMENTAL
Intervention: Left side placement
Number of subjects: 87
Study 26847368 — intervention group
Group type: COMPARATOR
Intervention: Back placement
Number of subjects: 87
Study 22965967 — intervention group
Group type: COMPARATOR
Intervention: Common standard arm with cytarabine- and anthracycline-based standard-dose remission induction and high-dose consolidation courses
Number of subjects: 2995
Study 22965967 — intervention group
Group type: COMPARATOR
Intervention: Common standard arm
Number of subjects: 2995
Study 20122356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical foot stimulation
Number of subjects: 40
Study 20122356 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 40
Study 17847604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontology for meta-analysis
Number of subjects: 0
Study 16162038 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Instruction (PI)
Number of subjects: 20
Study 16162038 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Study (SS)
Number of subjects: 20
Study 16162038 — intervention group
Group type: COMPARATOR
Intervention: Delayed Training (DT)
Number of subjects: 20
Study 11029607 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 81
Study 11029607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 9243149 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (100 mg 2 h infusion) followed by heparin (20 IU.kg‐1.h‐1)
Number of subjects: 50
Study 9243149 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (100,000 IU.h‐1 12 h infusion after an initial bolus of 250,000 IU over 15 min) followed by heparin (10 IU.kg‐1.h‐1)
Number of subjects: 50
Study 9243149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Recombinant tissue plasminogen activator and Streptokinase)
Number of subjects: 50
Study 8281592 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 923
Study 8281592 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron
Number of subjects: 923
Study 8281592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923
Study 8281592 — intervention group
Group type: COMPARATOR
Intervention: 1 mg ondansetron
Number of subjects: 923
Study 3329420 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (EG)
Number of subjects: 164
Study 3329420 — intervention group
Group type: COMPARATOR
Intervention: Regular postpartum care in hospital (CG)
Number of subjects: 164
Study 2828289 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 Gy in 15 fractions over 3 weeks (HD)
Number of subjects: 168
Study 2828289 — intervention group
Group type: COMPARATOR
Intervention: 25 Gy in ten fractions over 2 weeks (SD)
Number of subjects: 168
Study 31884309 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP
Number of subjects: 196
Study 31884309 — intervention group
Group type: COMPARATOR
Intervention: No-CPAP
Number of subjects: 196
Study 31884309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPAP and no-CPAP
Number of subjects: 196
Study 31884309 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence
Number of subjects: 196
Study 31884309 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 196
Study 31884309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 196
Study 31028597 — intervention group
Group type: EXPERIMENTAL
Intervention: Chain community pharmacies
Number of subjects: 12
Study 28038377 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Psychotherapy (brief‐IPT)
Number of subjects: 42
Study 28038377 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 42
Study 26403472 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic chewing tablets (ProBiora3), one tablet per day for one year
Number of subjects: 138
Study 26403472 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing tablets (identical tablets without bacteria)
Number of subjects: 138
Study 23036096 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose stavudine (30-40 mg)
Number of subjects: 60
Study 23036096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20-30 mg)
Number of subjects: 60
Study 23036096 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir (TDF, 300 mg)
Number of subjects: 60
Study 21740798 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA)
Number of subjects: 90
Study 21740798 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 90
Study 21740798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90
Study 19364890 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits (desktop videoconferencing)
Number of subjects: 175
Study 19364890 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face visits
Number of subjects: 175
Study 19364890 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits vs Face‐to‐face visits
Number of subjects: 175
Study 16707070 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (Group 3)
Number of subjects: 1009
Study 16707070 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy (compared with conservative treatment)
Number of subjects: 1009
Study 16707070 — intervention group
Group type: COMPARATOR
Intervention: Surgery (compared with sclerotherapy)
Number of subjects: 1009
Study 15086644 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once a day (n=424)
Number of subjects: 1042
Study 15086644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once a day (n=410)
Number of subjects: 1042
Study 15086644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=208)
Number of subjects: 1042
Study 15086644 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once a day
Number of subjects: 1042
Study 15086644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once a day
Number of subjects: 1042
Study 15086644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study 11710708 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with folic or folinic acid supplementation
Number of subjects: 236
Study 11710708 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate treatment without folic or folinic acid supplementation
Number of subjects: 236
Study 11710708 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of C677T mutation
Number of subjects: 236
Study 11710708 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy parameters of MTX treatment
Number of subjects: 236
Study 9385480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 800 mg/d
Number of subjects: 72
Study 9385480 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 500 mg/d
Number of subjects: 72
Study 7961231 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute altitude exposure (4,300 m)
Number of subjects: 8
Study 7961231 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic altitude exposure (4,300 m)
Number of subjects: 8
Study 7961231 — intervention group
Group type: EXPERIMENTAL
Intervention: Post 1 (return to sea level after 20 days at altitude)
Number of subjects: 8
Study 7961231 — intervention group
Group type: EXPERIMENTAL
Intervention: Post 2 (return to sea level after 20 days at altitude)
Number of subjects: 8
Study 7961231 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (MVC) of rested muscle
Number of subjects: 8
Study 3300312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norfloxacin
Number of subjects: 94
Study 3300312 — intervention group
Group type: COMPARATOR
Intervention: Parenteral agents
Number of subjects: 94
Study 31342604 — intervention group
Group type: EXPERIMENTAL
Intervention: Î²-Elemene
Number of subjects: 0
Study 28634056 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT) administered in 3 sessions with an energy flux density of 0.2, 0.4, and 0.6 mJ/mm2 (low, moderate, high intensity)
Number of subjects: 278
Study 28634056 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 278
Study 28634056 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors from logistic regression model
Number of subjects: 278
Study 25926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (27.5 g of protein, 15 g of carbohydrate, and 0.1 g of fat every night before sleep)
Number of subjects: 44
Study 25926415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 44
Study 25926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 44
Study 25926415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22569992 — intervention group
Group type: EXPERIMENTAL
Intervention: High hENT1 expression
Number of subjects: 95
Study 22569992 — intervention group
Group type: EXPERIMENTAL
Intervention: High RRM2 expression
Number of subjects: 95
Study 22569992 — intervention group
Group type: EXPERIMENTAL
Intervention: High ERCC1 expression
Number of subjects: 95
Study 22569992 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (subset analysis, n = 74) with high RRM2 and ERCC1 expression
Number of subjects: 95
Study 21198991 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - low probability group
Number of subjects: 1334
Study 21198991 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - intermediate probability group
Number of subjects: 1334
Study 21198991 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - high probability group
Number of subjects: 1334
Study 21198991 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - all probability groups
Number of subjects: 1334
Study 18382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fit mode (SF-mode)
Number of subjects: 40
Study 18382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-fit mode (MF-mode)
Number of subjects: 40
Study 16480404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg at bedtime
Number of subjects: 386
Study 16480404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 14607557 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified hMG
Number of subjects: 22
Study 14607557 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 22
Study 10798765 — intervention group
Group type: EXPERIMENTAL
Intervention: LO-CD2a/BTI-322 mAb
Number of subjects: 0
Study 10798765 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9068738 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy, 400 mg daily 1 week per month for 3 months
Number of subjects: 129
Study 9068738 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with itraconazole, 200 mg daily for 3 months
Number of subjects: 129
Study 8440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Data, Safety and Quality Review Group (DSQ) monitoring
Number of subjects: 0
Study 8440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a free-standing operations manual for the DSQ
Number of subjects: 0
Study 8440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of study investigators in developing the operations manual
Number of subjects: 0
Study 8440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of scientific integrity and patient safety
Number of subjects: 0
Study 8440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in study results
Number of subjects: 0
Study 3816530 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive incentive procedure (dose increase for drug-free urines)
Number of subjects: 20
Study 3816530 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative incentive procedure (dose decrease for drug-positive urines)
Number of subjects: 20
Study 3816530 — intervention group
Group type: COMPARATOR
Intervention: Dose decrease condition
Number of subjects: 20
Study 3816530 — intervention group
Group type: COMPARATOR
Intervention: Dose increase condition
Number of subjects: 20
Study 29326296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen therapy (ITB)
Number of subjects: 60
Study 29326296 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 60
Study 26573530 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with bupivacaine
Number of subjects: 113
Study 26573530 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block (PCB) with sodium chloride
Number of subjects: 113
Study 25493129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4S technique by ultrasound experts
Number of subjects: 150
Study 25493129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4S technique by emergency medicine residents (EMRs)
Number of subjects: 150
Study 22735431 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Weight Intervention (SBWI)
Number of subjects: 363
Study 22735431 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-Care Weight Loss Intervention (STEP)
Number of subjects: 363
Study 22735431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SBWI and STEP)
Number of subjects: 363
Study 20636896 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 21